China Life Private Equity Investment Company Limited

China Life Private Equity Investment Company Limited (国寿股权) is a specialized private equity investment platform under China Life Insurance, established in June 2016 . It manages the China Life Great Health Fund (国寿大健康基金), which was the first insurance-funded private equity investment fund approved after the former China Insurance Regulatory Commission issued relevant policies, and has since made dozens of investments in the healthcare sector . The firm is categorized among state-owned investment institutions active in new energy and is noted for having a relatively well-established ESG investment management committee . In healthcare specifically, it has appeared as a follow-on investor in companies such as Xiantong Medicine and as a backer of Yanming Biotech alongside other state capital and insurance-linked funds . Separately, "China Life Capital" (国寿资本) is listed among nearly ten institutions that received first-batch pilot qualifications for real estate private investment funds under a 2023 policy guidance .